By WSJ Staff
Shares in Moderna tumbled after the vaccine maker gave a revenue forecast for this year that fell far short of expectations, and said it would cut $1 billion of costs in 2025.
-- Shares recently traded at $33.14, down nearly 22%.
-- That put the stock on course for its lowest close since April 13, 2020, according to Dow Jones Market Data.
-- Such a fall would be largest percent decrease since the biotech company went public in December 2018.
Moderna said Monday it expects to bring in between $1.5 billion and $2.5 billion of revenue in 2025. Analysts polled by FactSet had expected revenue of about $2.92 billion.
The drug maker's financial update came as health sector leaders gathered for an annual industry conference. Read more:
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 13, 2025 11:02 ET (16:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。